GILD – gilead sciences, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day GILD SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
1.5%
8/7/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
8.6%
4/24/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
-2.8%
2/11/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
7.5%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/18 Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog] 9.5%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
Top News Decliners
3/20 Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00. -9.3%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
GILD – gilead sciences, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
GILD
SPY
QQQ
SPX
GILD – gilead sciences, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
GILD SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
12/24
10:06 am
gild
Low
Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise [Yahoo! Finance]
12/24
07:27 am
gild
Low
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration [Yahoo! Finance]
12/22
04:05 pm
gild
Low
Gilead Sciences to Present at Upcoming Investor Conference
12/22
11:03 am
gild
Low
Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance]
12/22
11:03 am
gild
Low
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 [Yahoo! Finance]
12/22
08:23 am
gild
Low
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes [Yahoo! Finance]
12/22
08:00 am
gild
Low
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
12/22
02:33 am
gild
Low
Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer [Yahoo! Finance]
12/19
04:09 pm
gild
Low
Why Gilead Sciences (GILD) Stock Is Up Today [Yahoo! Finance]
10/30/2025
04:02 pm
gild
1.5%
BEAT
8/7/2025
04:02 pm
gild
8.6%
BEAT
4/24/2025
04:02 pm
gild
-2.8%
BEAT
2/11/2025
04:02 pm
gild
7.5%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/15
07:02 am
Reiterates
Outperform
Outperform
Wolfe Research
Low
-0.1%
12/15
07:02 am
Reiterates
Outperform
Outperform
Wolfe Research
Low
-0.1%
12/12
12:07 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.4%
12/12
12:07 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.4%
12/10
03:04 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
0.3%
12/10
03:04 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
0.3%
12/9
08:11 am
Upgrades
Hold
UBS Group AG
Low
-1.5%
11/14
07:52 am
Upgrades
Strong-Buy
Scotiabank
Low
-1.4%
11/14
07:52 am
Upgrades
Strong-Buy
Scotiabank
Low
-1.4%
12/16
06:32 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 15 Filed by: Dickinson Andrew D
12/16
06:13 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 15 Filed by: Mercier Johanna
12/15
04:05 pm
gild
Low
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
12/15
04:04 pm
gild
Low
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
12/11
08:40 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 10 Filed by: Dickinson Andrew D
12/11
08:39 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 10 Filed by: O'Day Daniel Patrick
12/11
06:26 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 10 Filed by: Mercier Johanna
12/1
06:12 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Nov 28 Filed by: Bluestone Jeffrey
12/1
04:55 pm
gild
Medium
Form 4 GILEAD SCIENCES, INC. For: Nov 26 Filed by: Kramer Kelly A.
Show more
Top News Gainers
3/18 Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog] 9.5%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
Top News Decliners
3/20 Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00. -9.3%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%